Two case reports of pyoderma gangrenosum and systemic lupus erythematosus: A rare but nonfortuitous association?

Medicine (Baltimore)

Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debré Hospital, University Hospital, Reims Department of Internal Medicine and Infectious Diseases, Manchester Hospital, Charleville-Mézières Department of Dermatology, Robert Debré Hospital Laboratory of Pathol

Published: August 2018


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Rationale: Pyoderma gangrenosum (PG), like other neutrophilic dermatosis, may be associated with a variety of systemic disorders including inflammatory bowel diseases, rheumatoid arthritis, and hematologic disorders. Conversely, the association between PG and systemic lupus erythematosus (SLE) has rarely been reported.

Patient Concerns: We report here 2 cases of this association.

Diagnoses: The first case involves a 32-year-old woman who developed, 1 year after SLE diagnosis, 3 painful nodular lesions of PG on her face, and cervical area. The second case was observed in a 37-year-old woman referred for ulcerative nodular papules of PG on her legs, whereas she had been diagnosed with SLE 10 years before. SLE was inactive in the first case, whereas PG occurred during a lupus flare up in the second one.

Interventions: We found 23 previous cases of SLE and PG in the literature with most cases (12/20) occurring during a lupus flare.

Outcomes: Although rare, this association may be supported by common innate immunity dysregulation and abnormal neutrophil activation.

Lessons: PG and other neutrophilic diseases reported in patients with SLE may be added to the large clinical spectrum of cutaneous lesions observed in SLE.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112963PMC
http://dx.doi.org/10.1097/MD.0000000000011933DOI Listing

Publication Analysis

Top Keywords

pyoderma gangrenosum
8
systemic lupus
8
lupus erythematosus
8
sle
7
case
4
case reports
4
reports pyoderma
4
gangrenosum systemic
4
lupus
4
erythematosus rare
4

Similar Publications

Aim: To evaluate the therapeutic efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in the management of refractory perianal pyoderma gangrenosum (PG) under conditions of baseline immunosuppression and bone marrow suppression.

Methods: We present a 62-year-old male with a 4-month history of painful, progressive symmetrical perianal ulcerations diagnosed as PG, coexisting with condyloma acuminatum. The patient had a background of pure red cell aplasia and myasthenia gravis, and was undergoing chronic immunosuppressive therapy with prednisolone and tacrolimus.

View Article and Find Full Text PDF

Epidemiology and Management for Pediatric Chronic Wounds: A Systematic Review of the Current Literature.

J Surg Res

September 2025

Nationwide Children's Hospital, Abigail Wexner Research Institute, Columbus, Ohio; Department of Plastic and Reconstructive Surgery, Nationwide Children's Hospital, Columbus, Ohio; Pediatric Comprehensive Wound Program, Nationwide Children's Hospital, Columbus, Ohio. Electronic address: Jenny.Barker

Introduction: Chronic wounds affect approximately 10.5 million individuals annually in the United States. Although recent studies have highlighted a surge in chronic wound cases among younger populations, the collective burden of pediatric chronic wounds remains understudied.

View Article and Find Full Text PDF